Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Summary

This phase I trial studies the impact of taking drugs (agents) that target altered brain metabolism following standard of care brain radiotherapy. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. However, radiotherapy can also cause harmful effects to normal brain functioning. One drug, called anhydrous enol-oxaloacetate (AEO), has previously been studied in ischemic stroke, Alzheimer's disease, Parkinson's disease, and glioma. Drugs such as AEO may help preserve or restore healthy brain function after brain radiotherapy compared to the standard practice which consists of no drugs.

Timeline

Start

2025-10-20

Primary completion

2025-10-20

Completion

2025-10-20

Outcome

Outcome not reported

Stopped (Business): “Funding issues”

Drugs

Indications